These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33464936)

  • 21. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases.
    Brunelli SM; Blanchette CM; Claxton AJ; Roy D; Rossetti S; Gutierrez B
    Clinicoecon Outcomes Res; 2015; 7():65-72. PubMed ID: 25609987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.
    Ramanathan G; Periyasamy S; Lakkakula BV
    Nephrology (Carlton); 2014 Sep; 19(9):537-41. PubMed ID: 24824375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.
    Spithoven EM; Kramer A; Meijer E; Orskov B; Wanner C; Caskey F; Collart F; Finne P; Fogarty DG; Groothoff JW; Hoitsma A; Nogier MB; Postorino M; Ravani P; Zurriaga O; Jager KJ; Gansevoort RT; ; ; ; ;
    Kidney Int; 2014 Dec; 86(6):1244-52. PubMed ID: 24827775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.
    Gnanasambandan R; Elumalai R; Soundararajan P; Lakkakula BVKS
    Clin Exp Nephrol; 2016 Aug; 20(4):561-568. PubMed ID: 26482465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease.
    Yoo DJ; Agodoa L; Yuan CM; Abbott KC; Nee R
    BMC Nephrol; 2014 Feb; 15():39. PubMed ID: 24571546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost.
    Solid CA; Peter SA; Natwick T; Guo H; Collins AJ; Arduino JM
    Nephron; 2017; 136(2):54-61. PubMed ID: 28214902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and risk factors for kidney failure in patients with autosomal dominant polycystic kidney disease: A retrospective study.
    Park H; Paek JH; Kim Y; Park WY; Han S; Jin K
    Medicine (Baltimore); 2022 Nov; 101(47):e31838. PubMed ID: 36451428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B
    Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between depression, anxiety, quality of life levels, and the chronic kidney disease stage in the autosomal dominant polycystic kidney disease.
    Yarlioglu AM; Oguz EG; Gundogmus AG; Atilgan KG; Sahin H; Ayli MD
    Int Urol Nephrol; 2023 Apr; 55(4):983-992. PubMed ID: 36184721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience.
    Ozkok A; Akpinar TS; Tufan F; Kanitez NA; Uysal M; Guzel M; Caliskan Y; Alisir S; Yazici H; Ecder T
    Clin Exp Nephrol; 2013 Jun; 17(3):345-51. PubMed ID: 23085781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
    Ruggenenti P; Gentile G; Perico N; Perna A; Barcella L; Trillini M; Cortinovis M; Ferrer Siles CP; Reyes Loaeza JA; Aparicio MC; Fasolini G; Gaspari F; Martinetti D; Carrara F; Rubis N; Prandini S; Caroli A; Sharma K; Antiga L; Remuzzi A; Remuzzi G;
    Clin J Am Soc Nephrol; 2016 May; 11(5):785-794. PubMed ID: 26912555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe.
    Joly D; Quinn J; Mokiou S; O'Reilly K; Sánchez-Covisa J; Wang-Silvanto J; Doll H
    BMC Nephrol; 2020 Jul; 21(1):298. PubMed ID: 32709218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autosomal dominant polycystic kidney disease: Study of clinical characteristics in an Indian population.
    Vikrant S; Parashar A
    Saudi J Kidney Dis Transpl; 2017; 28(1):115-124. PubMed ID: 28098112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
    Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
    J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Yarlas A; Bjorner JB; Krasa H
    Kidney Med; 2024 Jan; 6(1):100755. PubMed ID: 38192435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysmetabolic markers predict outcomes in autosomal dominant polycystic kidney disease.
    Kocyigit I; Ozturk F; Eroglu E; Karaca Z; Kaynar AS; Cetin M; Tokgoz B; Sipahioglu MH; Bayramov R; Sen A; Oymak O; Ecder T; Axelsson J
    Clin Exp Nephrol; 2019 Sep; 23(9):1130-1140. PubMed ID: 31134465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.